The guidelines generated by the International Consensus Group on Bipolar I Depression are an interesting, important, and useful compilation of the clinical research on bipolar depression. They will ...

Moment of Clarity has published a new educational article titled “Spravato for Bipolar Depression Treatment“, providing an in-depth exploration of how esketamine therapy is being used to manage ...

Baylor College of Medicine received nearly $10 million in funding from the NIH BRAIN Initiative to study effective treatments for the depressive phase of bipolar disorder. In the span of five years, ...

Synthetic psilocybin with psychotherapy was effective and safe for patients with treatment-resistant bipolar depression, a small nonrandomized controlled trial suggested. Among 15 people with bipolar ...

A new paper in the journal Neuropsychopharmacology indicates that brain stimulation treatments such as electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS) were among the most ...

Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be used ...

If you’re living with bipolar disorder and standard treatments aren’t bringing relief, your provider might use the term “treatment-resistant.” It’s a label that can sound worryingly like “untreatable, ...